The significance of partial volume effect on the estimation of hypoxic tumour volume with [18F]FMISO PET/CT.

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Kafkaletos, Athanasios
- Mix, Michael
- Sachpazidis, Ilias
- Ruhle, Alexander
- Ruf, Juri
- Grosu, Anca L
- Nicolay, Nils H
- Baltas, Dimos
Grups d'Investigació
Abstract
BACKGROUND: The purpose of this study was to evaluate how a retrospective correction of the partial volume effect (PVE) in [18F]fluoromisonidazole (FMISO) PET imaging, affects the hypoxia discoverability within a gross tumour volume (GTV). This method is based on recovery coefficients (RC) and is tailored for low-contrast tracers such as FMISO. The first stage was the generation of the scanner's RC curves, using spheres with diameters from 10 to 37mm, and the same homogeneous activity concentration, positioned in lower activity concentration background. Six sphere-to-background contrast ratios were used, from 10.0:1, down to 2.0:1, in order to investigate the dependence of RC on both the volume and the contrast ratio. The second stage was to validate the recovery-coefficient correction method in a more complex environment of non-spherical lesions of different volumes and inhomogeneous activity concentration. Finally, we applied the correction method to a clinical dataset derived from a prospective imaging trial (DRKS00003830): forty nine head and neck squamous cell carcinoma (HNSCC) cases who had undergone FMISO PET/CT scanning for the quantification of tumour hypoxia before (W0), 2weeks (W2) and 5weeks (W5) after the beginning of radiotherapy. Here, PVE was found to cause an underestimation of the activity in small volumes with high FMISO signal.; RESULTS: The application of the proposed correction method resulted in a statistically significant increase of both the hypoxic subvolume (171% at W0, 691% at W2 and 4.60*103% at W5 with p<0.001) and the FMISO standardised uptake value (SUV) (27% at W0, 21% at W2 and by 25% at W5 with p<0.001) within the primary GTV.; CONCLUSIONS: The proposed PVE-correction method resulted in a statistically significant increase of the hypoxic fraction (HF) with p<0.001 and demonstrated results in better agreement with published HF data for HNSCC. To summarise, the proposed RC-based correction method can be a useful tool for a retrospective compensation against PVE. © 2024. The Author(s).
Dades de la publicació
- ISSN/ISSNe:
- 2197-7364, 2197-7364
- Tipus:
- Article
- Pàgines:
- -
- PubMed:
- 38722446
- Factor d'Impacte:
- 1,031 SCImago ℠
- Quartil:
- Q1 SCImago ℠
EJNMMI Physics Springer International Publishing AG
Cites Rebudes en Web of Science: 1
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Keywords
- Hypoxia; Partial volume effects; PET; FMISO; HNSCC
Projectes associats
OPTIMIZACION DE LA QUANTIFICACION EN IMAGEN POR TOMOGRAFIA POR EMISION DE POSITRONES (PET) PARA SU USO EN RADIOTERÀTIA
Investigador Principal: LUIS MARTÍ BONMATÍ
APOSTD2015/017 . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA; CONSELLERIA DE EDUCACION . 2015
3D-Printing phantoms for quality assurance in multimodality imaging.
Investigador Principal: MONTSERRAT CARLES FARIÑA
2022-155-1_CRC_AECC_CARLES . FUNDACIÓN CIENTÍFICA AECC . 2022
Implementación de la compensación del movimiento respiratorio en el diagnóstico y tratamiento radioterápico de pacientes con cáncer de pulmón: protocolos de imagen, segmentación del tumor y garantía de calidad del tratamiento.
Investigador Principal: MONTSERRAT CARLES FARIÑA
PI22/01604 . INSTITUTO DE SALUD CARLOS III . 2023
MATTO-GBM FCAECC-Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma.
Investigador Principal: LUIS MARTÍ BONMATÍ
TRANSCAN-3 JTC2022 . COMISION EUROPEA . 2023
QA-THOMASA - UCIE 22-24
Investigador Principal: MONTSERRAT CARLES FARIÑA
INNVA2/2022/1_THOMASA . 2022
Contrato PFIS 2023. CARMEN SALVADOR RIBES
Investigador Principal: MONTSERRAT CARLES FARIÑA
FI23/00097 . INSTITUTO DE SALUD CARLOS III . 2024
Contrato Miguel Servet 2023. MONTSERRAT CARLES FARIÑA
Investigador Principal: MONTSERRAT CARLES FARIÑA
CP23/00106 . INSTITUTO DE SALUD CARLOS III . 2024
MATTO-GBM ISCIII-Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma.
Investigador Principal: LUIS MARTÍ BONMATÍ
AC23_1/00012 . COMISION EUROPEA . 2024
Acción de fortalecimiento institucional transversal para una medicina 5P (AFIT-5P)
Investigador Principal: JAVIER DE LA RUBIA COMOS
FORT23/00021 . INSTITUTO DE SALUD CARLOS III . 2024
BIOBANCO DEL HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE (BIOBANCO LA FE). PLATAFORMA DE BIOBANCOS Y BIOMODELOS
Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA
PT23/00166 . INSTITUTO DE SALUD CARLOS III . 2024